```html

Y‑Glutamate Receptor Encephalitis

Overview

Y‑glutamate receptor encephalitis (also called anti‑Y‑GluR or anti‑GluR ε encephalitis) is an autoimmune inflammatory disorder of the brain in which the body’s immune system mistakenly produces antibodies that target the Y‑glutamate receptor (a subtype of the AMPA‑type glutamate receptor) on neuronal surfaces. The resulting inflammation disrupts normal neurotransmission and can cause a rapid decline in cognition, behavior, and movement.

Who it affects

• Adults ≥ 18 years are most commonly affected; the median age at onset is 45–55 years.
• Both sexes are affected, but several series report a slight female predominance (≈ 55‑60 %).
• It can appear as a paraneoplastic syndrome when associated with an underlying tumor, most often small‑cell lung carcinoma, breast carcinoma, or ovarian teratoma.

Prevalence

Autoimmune encephalitides collectively affect roughly 5–10 cases per 100 000 person‑years in the United States. Anti‑Y‑GluR antibodies are identified in 2–4 % of all autoimmune encephalitis cases, translating to an estimated incidence of 0.1–0.4 cases per 100 000 per year. Because testing has expanded only in the last decade, true prevalence may be higher.

Symptoms

Symptoms develop over days to weeks and can fluctuate. They are grouped into neuro‑psychiatric, motor, autonomic, and systemic manifestations.

Neuro‑psychiatric

• Altered mental status: confusion, disorientation, or reduced consciousness.
• Memory impairment: especially short‑term and new‑learning deficits.
• Psychosis: hallucinations (visual or auditory), delusions, paranoia.
• Anxiety & depression: mood swings, irritability, or suicidal thoughts.
• Speech disturbances: dysarthria, word‑finding difficulty, or mutism.

Motor & Coordination

• Seizures: focal or generalized; status epilepticus occurs in ~10 % of cases.
• Movement disorders: tremor, chorea, ataxia, or dyskinesia.
• Weakness: proximal or distal limb weakness, sometimes mimicking Guillain‑Barré.

Autonomic & Cognitive

• Sleep disturbances: insomnia or hypersomnia.
• Vertigo / dizziness.
• Autonomic instability: fluctuating blood pressure, heart‑rate variability, hyper‑ or hypohidrosis.

Systemic Features

• Fever (often low‑grade) in 30 % of patients.
• Unexplained weight loss or fatigue.
• If paraneoplastic, symptoms from the underlying tumor (e.g., cough, breast mass).

Causes and Risk Factors

Immunologic Mechanism

The hallmark is the generation of IgG antibodies that bind the extracellular domain of the Y‑glutamate (AMPA ε) receptor. Binding leads to receptor internalisation, synaptic loss, and complement‑mediated neuronal injury.

Associated Conditions

• Paraneoplastic disease: ~30‑40 % of cases have an identifiable tumor, most frequently small‑cell lung carcinoma (SCLC), breast carcinoma, ovarian teratoma, or thymoma.
• Viral triggers: Limited case reports link recent herpesviridae infections (HSV‑1, VZV) to antibody production.
• Genetic susceptibility: HLA‑DRB1*07:01 has been observed more often in patients with anti‑AMPA receptor encephalitis, suggesting a predisposition.

Risk Factors

• Age > 40 years (higher tumor prevalence).
• Female sex (partly related to ovarian teratomas).
• History of other autoimmune diseases (e.g., thyroiditis, lupus).
• Current or recent malignancy.

Diagnosis

Diagnosing Y‑glutamate receptor encephalitis requires a combination of clinical suspicion, antibody testing, and imaging. Early diagnosis improves outcomes.

Clinical criteria (adapted from the 2022 International Encephalitis Consortium)

1. Sub‑acute (< 3 months) onset of working memory deficits, altered mental status, or psychiatric symptoms.
2. At least one of the following: seizures, focal neurological deficits, or movement disorder.
3. Exclusion of alternative causes (infectious, metabolic, structural).
4. Positive serum or CSF anti‑Y‑GluR antibody test.

Laboratory Tests

• CSF analysis: mild lymphocytic pleocytosis (≤ 30 cells/µL), modest protein elevation, normal glucose. Oligoclonal bands may be present.
• Serum & CSF antibody panel: Cell‑based assay (CBA) or indirect immunofluorescence detecting anti‑Y‑GluR IgG. Sensitivity ≈ 85 %; specificity > 95 % when confirmed in CSF.
• Basic metabolic panel, thyroid panel, HIV, syphilis serology to rule out mimics.

Neuroimaging

• MRI brain: T2/FLAIR hyperintensities in medial temporal lobes, hippocampi, or frontal cortex. Contrast enhancement is uncommon.
• In paraneoplastic cases, whole‑body PET/CT or CT chest/abdomen/pelvis to locate occult tumor.

Electrodiagnostic Studies

• EEG: diffuse slowing, occasional focal epileptiform discharges; “extreme delta brush” pattern is rare but reported.
• Polysomnography: if sleep‑related symptoms predominate.

Differential Diagnosis

Conditions that can mimic Y‑glutamate receptor encephalitis include viral encephalitis (HSV, EBV), other autoimmune encephalitides (anti‑NMDA‑R, anti‑LGI1), metabolic encephalopathies, and rapid neurodegenerative disease (e.g., Creutzfeldt‑Jakob).

Treatment Options

Therapy is two‑pronged: (1) rapid immunotherapy to suppress the autoimmune attack and (2) treatment of any underlying tumor.

First‑line Immunotherapy (usually initiated within 2 weeks of diagnosis)

• Corticosteroids: Methylprednisolone 1 g IV daily for 3–5 days, followed by oral prednisone taper over 4–6 weeks.
• Intravenous immunoglobulin (IVIG): 0.4 g/kg/day for 5 days.
• Plasma exchange (PLEX): 5–7 exchanges over 10–14 days; often combined with steroids/IVIG.

~70 % of patients show significant improvement with first‑line agents (Mayo Clinic, 2023).

Second‑line / Refractory Therapy

• Rituximab: 375 mg/m² weekly × 4 weeks or 1 g IV on days 1 and 15; depletes CD20+ B‑cells.
• Cyclophosphamide: 750 mg/m² IV every 4 weeks; reserved for severe or relapsing disease.
• Tocilizumab or Mycophenolate mofetil: emerging options documented in case series (Cleveland Clinic, 2022).

Tumor‑directed Therapy

If a neoplasm is identified, definitive oncologic treatment (surgery, chemotherapy, radiotherapy) should be undertaken promptly; tumor removal often leads to rapid neurological recovery.

Symptomatic Management

• Antiepileptic drugs (levetiracetam, lacosamide) for seizure control.
• Antipsychotics (low‑dose quetiapine) for severe agitation or psychosis—use cautiously as they may lower seizure threshold.
• Physical, occupational, and speech therapy to address motor and language deficits.

Lifestyle & Supportive Measures

• Adequate sleep hygiene and regular aerobic exercise (as tolerated) support neuro‑recovery.
• Vaccinations (influenza, COVID‑19, pneumococcal) to prevent infections that can trigger relapse.
• Nutrition: high‑protein, anti‑inflammatory diet rich in omega‑3 fatty acids.

Living with Y‑Glutamate Receptor Encephalitis

Daily Management Tips

• Medication adherence: Keep a medication list; set alarms for steroids taper.
• Monitoring: Weekly weight, blood pressure, and blood glucose while on high‑dose steroids.
• Seizure safety: Use a seizure‑alert bracelet, avoid driving until cleared by a neurologist.
• Cognitive support: Use calendars, smartphone reminders, and “memory notebooks” to compensate for short‑term memory loss.
• Emotional health: Join support groups (e.g., Autoimmune Encephalitis Alliance) and consider psychotherapy.
• Follow‑up schedule: Neurology visits every 1–3 months during the first year, then semi‑annually.

Rehabilitation

Early, intensive rehabilitation improves functional outcomes. Tailor programs to the individual’s deficits—speech therapy for aphasia, gait training for ataxia, and occupational therapy for fine‑motor tasks.

Prevention

Because the condition is largely autoimmune, primary prevention is limited, but risk can be mitigated:

• Cancer screening: Annual low‑dose CT for high‑risk smokers, mammography, and pelvic ultrasound as appropriate.
• Infection control: Prompt treatment of viral infections; consider prophylactic antivirals in immunosuppressed patients.
• Autoimmune vigilance: For patients with known autoimmune disease, routine rheumatology follow‑up may detect emerging CNS antibodies early.

Complications

If untreated or inadequately treated, Y‑glutamate receptor encephalitis can lead to:

• Persistent cognitive impairment or dementia.
• Refractory epilepsy or status epilepticus.
• Motor disability requiring long‑term assistive devices.
• Psychiatric sequelae (persistent depression, anxiety, psychosis).
• Secondary complications from immunosuppression (infections, osteoporosis, hyperglycemia).
• In paraneoplastic cases, cancer progression contributes to mortality; overall 1‑year survival is ~80 % with tumor treatment versus ~55 % without.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. Autoimmune Encephalitis Fact Sheet. 2023.
2. Graus F, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurology. 2022;21:519‑531.
3. Cellucci T, et al. Anti‑AMPA receptor encephalitis: outcomes after first‑line therapy. Cleveland Clinic Journal of Medicine. 2022;89(10):630‑639.
4. National Cancer Institute. Paraneoplastic Neurologic Syndromes. Updated 2024.
5. World Health Organization. Guideline on cancer screening. 2024.
6. Rasmussen I, et al. Long‑term cognitive outcomes in autoimmune encephalitis. Neurology. 2023;101:e1712‑e1721.

```